tiprankstipranks
Ercros SA (ES:ECR)
BME:ECR
Want to see ES:ECR full AI Analyst Report?

Ercros SA (ECR) Price & Analysis

5 Followers

ECR Stock Chart & Stats

€3.43
€0.00(0.00%)
At close: 4:00 PM EST
€3.43
€0.00(0.00%)

Bulls Say, Bears Say

Bulls Say
Cash Generation ResilienceSustained positive operating and free cash flow in 2025 shows the business can convert operations into liquidity even amid profit pressure. This cash generation provides a durable buffer for working capital, short-term obligations and selective reinvestment, supporting stability over coming months.
Essential Industrial Chemicals BusinessErcros supplies basic chemicals used across industry, a structurally essential product set. Revenue drivers (volume and pass-through of raw‑material/energy costs) reflect a predictable demand base and contract dynamics that support recovery as industrial activity normalizes over the medium term.
Moderate Absolute LeverageAlthough leverage has risen, debt remaining below equity indicates the balance sheet is not at extreme risk. That position gives management room to refinance or access credit, helping them manage restructuring or working‑capital needs while pursuing operational improvements over the next several months.
Bears Say
Profitability DeteriorationA material swing from multi‑year profit to recurring losses signals structural margin pressure or demand weakening. Persistent losses erode equity, limit capacity to fund capex or sustain investments, and may force cost cuts or asset sales, constraining strategic options over the medium term.
Declining Revenue TrendA multi‑year top‑line decline reduces scale and increases unit cost exposure by weakening fixed‑cost absorption. Continued revenue erosion makes margin recovery harder, pressures cash conversion, and raises the risk that operational fixes will not restore prior profitability within a few quarters.
Volatile Cash Flow GenerationHigh variability in free cash flow complicates planning and increases reliance on short‑term funding when swings occur. Volatility raises refinancing and liquidity risk, can elevate financing costs, and may limit consistent investment or deleveraging efforts over the 2–6 month horizon.

Ercros SA News

ECR FAQ

What was Ercros SA’s price range in the past 12 months?
Ercros SA lowest stock price was €2.23 and its highest was €3.48 in the past 12 months.
    What is Ercros SA’s market cap?
    Ercros SA’s market cap is €316.37M.
      When is Ercros SA’s upcoming earnings report date?
      Ercros SA’s upcoming earnings report date is Jul 29, 2026 which is in 37 days.
        How were Ercros SA’s earnings last quarter?
        Ercros SA released its earnings results on May 20, 2026. The company reported -€0.266 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.266.
          Is Ercros SA overvalued?
          According to Wall Street analysts Ercros SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Ercros SA pay dividends?
            Ercros SA pays a Annually dividend of €0.096 which represents an annual dividend yield of 2.27%. See more information on Ercros SA dividends here
              What is Ercros SA’s EPS estimate?
              Ercros SA’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Ercros SA have?
              Ercros SA has 91,436,195 shares outstanding.
                What happened to Ercros SA’s price movement after its last earnings report?
                Ercros SA reported an EPS of -€0.266 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.146%.
                  Which hedge fund is a major shareholder of Ercros SA?
                  Currently, no hedge funds are holding shares in ES:ECR
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Ercros SA

                    Ercros, S.A. is a Spanish industrial group primarily engaged in the production and distribution of basic chemicals, intermediate chemical products, and pharmaceuticals. The company also extends its market reach through export activities. Its diverse operations are structured into three main divisions: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment manufactures a broad spectrum of products, including ammonia, bioplastics, various caustic solutions (potash and soda), chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers. These compounds serve as vital industrial intermediates, essential for applications such as purifying drinking and wastewater, maintaining swimming pools, bleaching paper and textiles, and formulating detergents, solvents, and strippers. They also find use in producing printing inks, animal feed, and cooling equipment. The Intermediate Chemicals division supplies products like formaldehyde, various glues and resins, molding powders, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate. These are crucial for manufacturing wood-based panels like chipboards, decorative laminates, and plywoods, as well as resins, paints, and varnishes for the furniture and decoration sectors. Furthermore, they are integral to producing electrical components such as plugs and switches, and contribute to household, sanitary, and packaging materials within the textile tanning industry. Ercros's Pharmacy segment focuses on developing and producing active pharmaceutical ingredients (APIs) and intermediate compounds. Its portfolio includes agents for various therapeutic areas, such as bacterial infections (e.g., azithromycin, clarithromycin, erythromycins, calcium and sodium fosfomycin, fosfomycin trometamol, fusidic acid), high cholesterol (amlodipine besylate), ulcers (famotidine), and fungal infections. With a rich history, Ercros, S.A. was established in 1817 and maintains its corporate headquarters in Barcelona, Spain.

                    Ercros SA (ECR) Earnings & Revenues

                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Faes Farma
                    Grifols
                    LABORATORIO REIG JOFRE
                    Laboratorios Farmaceuticos Rovi
                    Repsol

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks